215 related articles for article (PubMed ID: 22152173)
1. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Simpson KN; Rajagopalan R; Dietz B
Adv Ther; 2009 Feb; 26(2):185-93. PubMed ID: 19219410
[TBL] [Abstract][Full Text] [Related]
3. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
[TBL] [Abstract][Full Text] [Related]
6. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Ahmed BS; Phelps BR; Reuben EB; Ferris RE
Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Simpson KN; Jones WJ; Rajagopalan R; Dietz B
Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
12. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
Simpson KN; Luo MP; Chumney E; Sun E; Brun S; Ashraf T
HIV Clin Trials; 2004; 5(5):294-304. PubMed ID: 15562370
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Thuresson PO; Heeg B; Lescrauwaet B; Sennfält K; Alaeus A; Neubauer A
Scand J Infect Dis; 2011 Apr; 43(4):304-12. PubMed ID: 21231811
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of group psychotherapy for depression in Uganda.
Siskind D; Baingana F; Kim J
J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
[TBL] [Abstract][Full Text] [Related]
18. The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
Schneider K; Nwizu C; Kaplan R; Anderson J; Wilson DP; Emery S; Cooper DA; Boyd MA
PLoS One; 2013; 8(2):e54435. PubMed ID: 23457450
[TBL] [Abstract][Full Text] [Related]
19. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.
Marseille E; Saba J; Muyingo S; Kahn JG
AIDS; 2006 Apr; 20(6):907-14. PubMed ID: 16549976
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
